

DETAILED CONTENTS

<u>CHAPTER</u>		<u>PAGE</u>
1	STUDY ORGANIZATION	1-1
1.1	Participating Units	1-1
1.1.1	Transplant Centers	1-1
1.1.2	Cord Blood Banks	1-3
1.1.3	Medical Coordinating Center	1-4
1.1.4	National Heart, Lung and Blood Institute Program Office	1-5
1.2	Study Administration	1-5
1.2.1	Study Chairperson	1-5
1.2.2	Data and Safety Monitoring Board	1-7
	1.2.2.1 Purpose	1-7
	1.2.2.2 Meetings	1-8
1.2.3	Steering Committee	1-9
1.2.4	Executive Committee	1-10
1.2.5	Technical Subcommittees	1-10
1.2.6	Publications Committee	1-12
2	STUDY POLICIES	2-1
2.1	Adherence to Manual of Procedures	2-1
	2.1.1 FDA Form 1572 (Statement of Investigator)	2-1
	2.1.2 <i>Curricula Vitae</i> - Principal Investigators and Co-investigators	2-1
2.2	Informed Consent	2-1
2.3	Protection of Human Subjects	2-2
2.4	Disclosure of Study Results	2-2
2.5	Access to Interim Endpoint Data	2-2
2.6	Scientific Publications and Presentations	2-2
	2.6.1 Generation of Publications and Presentations	2-2
	2.6.2 Editorial Review	2-3
	2.6.3 Authorship	2-3
	2.6.4 Acknowledgments	2-3
2.7	Ancillary Studies	2-3
	2.7.1 Definition of Ancillary Studies	2-3
	2.7.2 Approval of Ancillary Studies	2-4
	2.7.2.1 Funding of Ancillary Studies	2-5
	2.7.2.2 Publication of Ancillary Study Results	2-5
3	ADVERSE EXPERIENCES REPORTING	3-1
3.1	Definition of Adverse Experience	3-1
3.2	Adverse Experience Reporting and Management	3-2
	3.2.1 Medical Coordinating Center Reporting	3-2

<u>CHAPTER</u>		<u>PAGE</u>
4	DATA ANALYSIS AND REPORTING	4-1
4.1	Analysis Plan	4-1
4.1.1	Specification of Analysis Database	4-1
4.1.2	Reports for Publication	4-1
4.2	Expected Assessments of the Database for Quality Control	4-2
4.2.1	Database Quality	4-2
4.2.1.1	Duplicate and Error Checks	4-2
4.2.1.2	Delinquent Data	4-2
4.2.1.3	Key Entry Errors	4-3
4.2.1.4	Database Integrity	4-3
4.2.2	Operational Statistics	4-3
4.2.3	Patient Characteristics	4-3
4.2.4	Outcome Variables, Morbidity, and Mortality	4-3
4.3	Reporting	4-4
4.3.1	Reports to the Steering Committee and Technical Subcommittees	4-4
4.3.2	Reports to the Data and Safety Monitoring Board	4-4
4.3.3	Scientific Reports	4-5
5	QUALITY ENHANCEMENT	5-1
5.1	Recruiting Adequate Numbers of Patients	5-2
5.1.1	Anticipated Accrual of Minority and Female Subjects	5-2
5.2	Preventing Dropouts and Missed Contacts	5-3
5.3	Internal Transplant Center Monitoring	5-4
5.3.1	Principal Investigator	5-4
5.3.2	Clinic Monitor	5-4
5.4	External Transplant Center Monitoring	5-4
5.4.1	Data Editing	5-4
5.4.2	Computer Virus Protection	5-5
5.4.3	Protocol Review Calls	5-5
5.4.4	Site Visits (Protocol Review Visits)	5-6
5.5	References	5-7
6	TRANSPLANT CENTER PROCEDURES	6-1
6.1	Staffing and Organization	6-1
6.2	Functions of the Principal Investigator	6-1
6.3	Functions of the Clinic Coordinator	6-1
6.4	Recruitment	6-2
6.5	Eligibility Screening	6-3
6.6	Scheduling Patient Appointments	6-3
6.7	Checking Completed Forms	6-3
6.8	Transferring Patients	6-4

<u>CHAPTER</u>		<u>PAGE</u>
7	MEDICAL COORDINATING CENTER PROCEDURES	7-1
7.1	Staffing and Organization	7-1
7.2	Coordination and Administration	7-1
7.2.1	Roster of COBLT Study Personnel	7-1
7.2.2	Committee Support	7-2
7.2.3	Documentation	7-2
7.3	Study Planning	7-3
7.4	Data Management	7-3
7.5	Data Analysis and Reporting	7-4
8	COBLT CORD BLOOD BANK SEARCH PROCEDURES	8-1
8.1	Preliminary Search	8-1
8.1.1	COBLT Search Report	8-3
8.1.2	Selecting a COBLT CBU for a Formal Search	8-4
8.2	Formal Search	8-4
8.3	COBLT CBU Reservation	8-5
8.4	Request for Shipment of a Reserved COBLT Unit	8-6
8.5	Confirmation of Receipt of Cord Blood Unit	8-6
8.6	Multiple Center Searches for a Recipient and Transferring Searches	8-7
8.7	Cord Blood Units from Non-COBLT Banks	8-7
8.8	Search Forms	8-16
8.8.1	Preliminary Search Form	8-16
8.8.2	Formal Search Form	8-17
8.8.3	CBU Reservation Form	8-18
8.8.4	Search Update Form	8-19
8.8.5	Search Transfer Form	8-20
9	TRANSPLANT CENTER LABORATORY PROCEDURES	9-1
9.1	Immune Reconstitution Assays	9-1
9.1.1	Introduction and Objectives	9-1
9.1.2	Background	9-1
9.1.3	Specific Aim 1 - Production of New Lymphocytes	9-4
9.1.4	Specific Aim 2 - Antigen Specific T Cell Function	9-6
9.1.5	Specific Aim 3 - T and B Cell Cooperation	9-7
9.1.6	Collecting and Shipping of Peripheral Blood Samples	9-7
9.1.7	References	9-7
9.2	Thawing COBLT Cryopreserved Cord Blood Units for Transplantation	9-8
9.2.1	CBU Thawing Procedures	9-8
9.2.2	CBU Thawing Certification Requirements for Transplant Centers	9-9
9.2.3	Requesting CBUs for Thawing Certification	9-9
9.2.4	Obtaining Certification to Thaw COBLT CBUs	9-10
9.2.5	Maintaining Certification	9-10
9.2.6	Requesting Cell Wash/Infusion Bag Sets	9-10
9.3	Methods for Busulfan Dose Adjustment	9-13
9.4	Pre- and Post-Transplant Samples	9-15
9.4.1	Blood Draws for Chimerism Studies	9-15
9.4.2	CBU Sample for Retrospective HLA Typing	9-15
9.4.3	Blood Draws for Retrospective HLA Typing	9-16

<u>CHAPTER</u>		<u>PAGE</u>
10	DATA COLLECTION	10-1
10.1	Data Collection Procedures	10-1
10.1.1	Training and Certification	10-1
10.1.2	Forms Completion	10-1
10.1.3	Forms Submission and Missing Forms	10-1
10.1.4	Missing and Incorrectly Coded Data	10-2
10.1.5	Ordering Forms	10-2
10.1.6	Additional Reporting Requirements	10-3
10.2	Forms and Instructions	10-6
10.2.1	Eligibility Form	10-6
10.2.2A	CBU Thawing Form	10-12
10.2.2B	CBU Infusion Form	10-14
10.2.3	Acute GVHD Weekly Assessment	10-15
10.2.4	Toxicity Form	10-17
10.2.5	Hematopoiesis Assessment - Neutrophils	10-18
10.2.6	Hematopoiesis Assessment - Red Cells	10-19
10.2.7	Specimen Submission Form - Immune Reconstitution	10-20
10.2.8	Post-Transplant Infection Form	10-21
10.2.9	Re-Admission Form	10-22
10.2.10	Relapse Form	10-23
10.2.11	Adverse Experience Form	10-27
10.3	NMDP/IBMTR Forms and Instructions	10-29
10.3.1A	Form 120: Recipient Baseline and Transplant Data	10-29
10.3.1B	Form 120 Insert I – Acute Myelogenous Leukemia	10-30
10.3.1C	Form 120 Insert II – Acute Lymphoblastic Leukemia	10-31
10.3.1D	Form 120 Insert III – Chronic Myelogenous Leukemia (CML)	10-32
10.3.1E	Form 120 Insert IV – Other Leukemias	10-33
10.3.1F	Form 120 Insert V – Myelodysplasia/Myeloproliferative Disorders	10-34
10.3.1G	Form 120 Insert VI – Multiple Myeloma	10-35
10.3.1H	Form 120 Insert VII – Other Malignancy	10-36
10.3.1I	Form 120 Insert VIII – Aplastic Anemia	10-37
10.3.1J	Form 120 Insert IX – Hodgkin and Non-Hodgkin Lymphoma	10-38
10.3.1K	Form 120 Insert X – Severe Combined Immunodeficiency (SCID)	10-39
10.3.1L	Form 120 Insert XI – Wiskott Aldrich Syndrome (WAS)	10-40
10.3.1M	Form 120 Insert XIII – Leukodystrophies	10-41
10.3.1N	Form 120 Insert XIV – Mucopolysaccharidoses and Other Storage Diseases	10-42
10.3.2	IBMTR Cord Blood Transplant Insert	10-43
10.3.3A	Form 130: 100-Day Follow-Up Visit of Recipient	10-44
10.3.3B	Form 130 Post Transplant Follow-up Form Insert I– Severe Combined Immunodeficiency (SCIDS)	10-45
10.3.3C	Form 130 Post Transplant Follow-up Form Insert II– Wiskott Aldrich Syndrome (WAS)	10-46
10.3.3D	Form 130 Post Transplant Follow-up Form Insert III– Information for Hodgkin and Non-Hodgkin Lymphoma	10-47
10.3.4A	Form 140: 6-Month to 2-Year Follow-Up Visit of Recipient	10-48
10.3.4B	Form 130 Post Transplant Follow-up Form Insert I– Severe Combined Immunodeficiency (SCIDS)	10-49
10.3.4C	Form 130 Post Transplant Follow-up Form Insert II– Wiskott Aldrich Syndrome (WAS)	10-50

<u>CHAPTER</u>		<u>PAGE</u>
10	DATA COLLECTION (continued)	
	10.3.4D Form 130 Post Transplant Follow-up Form Insert III– Information for Hodgkin and Non-Hodgkin Lymphoma	10-51
	10.3.5 Form 150: Yearly Follow-Up for Greater Than 2 Years Post-Transplant	10-52
	10.3.6 Form 160: Leukemia and MDS Yearly Follow-up for Relapse Post-Stem Cell Transplant	10-53
	10.3.7 Form 190: Recipient Death Information	10-54
10.4	Data Management and Reporting	10-55
	10.4.1 Forms Mail Log	10-55
	10.4.2 Supplementary Forms Request	10-56
	10.4.3 Monthly Recruitment Report	10-57
	10.4.4 COBLT Bag Order Form	10-59
 <u>APPENDIX</u>		 <u>PAGE</u>
A	Roster	A-1
B	Investigators Brochure	B-1
 <u>EXHIBITS</u>		
1-1	COBLT Study Participating Units	1-2
1-2	Organization Chart	1-6
8-0	HLA Mappings Menu Selection	8-1
8-1-1	Add/Update Search Menu Selection	8-1
8-1-2	Add/Update Page Dialogue Box	8-2
8-1-1-1	Search Report	8-3
8-2-1	Formal Search Dialogue Box	8-4
8-2-2	Recipient Confirmatory Typing Dialogue Box	8-5
8-3-1	CBU Reservation Dialogue Box	8-5
8-3-2	CBU Reservation Dialogue Box	8-5
 <u>TABLES</u>		
8.1.1	Search Report Score and Typing Grade	8-2
9.1.3.1	Schedule of Immune Evaluation	9-5
9.1.3.2	Monoclonal Antibody Panel for Immunophenotyping - Immune Reconstitution	9-6
10.1.1	Forms Submission Schedule	10-4
10.1.2	Criteria for Forms Submission	10-5
 <u>FIGURES</u>		
8.1	COBLT CBU Searching and Reserving	8-8
8.2	Confirmatory HLA Typing Process by COBLT Laboratory	8-9
8.3	Confirmatory Typing Report – Recipient	8-10
8.4	Confirmatory Typing Report – COBLT Cord Blood Unit	8-11
8.5A	Recipient Sample Shipping Notification	8-12
8.5B	Non-COBLT Cord Blood Unit Sample Shipping Notification	8-13
8.6	Typing Results – Recipient	8-14
8.7	Confirmation of Registration/CBU Release Request	8-15
9.1	Busulfan Pharmacokinetics	9-14